Merck & Co., Inc. $MRK Stock Acquired by CoreCap Advisors LLC

CoreCap Advisors LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 8.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 66,609 shares of the company’s stock after acquiring an additional 5,124 shares during the period. CoreCap Advisors LLC’s holdings in Merck & Co., Inc. were worth $9,679,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. lifted its stake in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp boosted its position in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after buying an additional 1,087,583 shares during the period. Wellington Management Group LLP grew its stake in shares of Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the last quarter. Bank of America Corp DE increased its stake in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Finally, Invesco Ltd. lifted its position in Merck & Co., Inc. by 3.5% in the fourth quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock valued at $2,162,691,000 after purchasing an additional 701,249 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the sale, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. This represents a 9.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 228,238 shares of company stock worth $29,977,783. Insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MRK shares. Morgan Stanley dropped their price objective on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday. CICC Research began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Rothschild & Co Redburn upped their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 6th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a research report on Wednesday, August 12th. Finally, Bank of America raised their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Seventeen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $151.32.

Merck & Co., Inc. Trading Down 0.2%

Shares of MRK stock traded down $0.34 during trading hours on Thursday, reaching $142.45. The company’s stock had a trading volume of 8,404,711 shares, compared to its average volume of 10,662,183. The stock has a market capitalization of $351.45 billion, a P/E ratio of 113.96, a P/E/G ratio of 6.18 and a beta of 0.21. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The firm’s fifty day simple moving average is $143.34 and its 200 day simple moving average is $127.96. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved the combination of Merck’s WELIREG and LENVIMA for adults with advanced renal cell carcinoma previously treated with PD-1/PD-L1 therapy. The approval expands Merck’s oncology portfolio and could create additional revenue opportunities. Merck also started a first-in-human Phase I trial using Cyprumed’s oral peptide-delivery platform, adding a new pipeline initiative. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating and a $177 price target despite trimming its target from $179, implying substantial potential upside based on the referenced price. Cantor Fitzgerald also raised its target to $145, although it retained a neutral rating. Analyst Price Target Updates
• Neutral Sentiment: Value-focused coverage comparing Merck with Innoviva highlights the investment trade-off between Merck’s scale and established products and concerns about valuation and future growth. INVA vs. MRK: Which Stock Is the Better Value Option?
• Negative Sentiment: A Dutch court issued an injunction blocking Merck from selling subcutaneous Keytruda in eight European markets following Halozyme’s patent dispute. The ruling could delay or restrict commercialization of the newer formulation and increases legal and competitive risk around Merck’s most important product. Merck’s Keytruda Is Dealt a Legal Setback
• Negative Sentiment: Industry coverage identifies Merck as particularly exposed to near-term generic competition as major patents expire. That patent-cliff risk may weigh on longer-term growth expectations, especially given Keytruda’s importance to the company. Pharma’s $500B Patent Problem Will Come in Waves

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.